Patients with AID mutations that disrupt AID deaminase activity have impaired CSR and/or SHM and impaired antibody response that leads to prolonged infection, a syndrome known as hyper-IgM immunodeficiency [1,49,50]. The gene discussed is AICDA; the disease is infection.